title: Development of cell-mediated immunity to Marek's disease tumor cells in chickens inoculated with Marek's disease vaccines.
abstract: Chickens inoculated with herpesvirus of turkeys or with apathogenic or attenuated vaccine strains of Marek's disease virus (MDV) developed a T-cell-mediated immune response to Marek's disease (MD) tumor cells. This immune response was detected in a 4-hour 51Cr-release assay in which effector cells obtained from spleens of vaccinated chickens were reacted with 51Cr-labeled target cells of an MD lymphoblastoid cell line (MSB-1). The cytotoxic effector cells generated by the vaccine viruses had characteristics similar to those noted previously for anti-MSB-1 effector cells generated by MDV. The immune response was specific to MSB-1 cells, because another target cell line (TLT) antigenically unrelated to MSB-1 cells was not lysed by the effector cells nor did the unrelated target cells inhibit the cytotoxicity of effector cells against MSB-1 target in a cold-target inhibition assay. Because MSB-1 cells contain MD tumor-associated surface antigen, we postulated that the immune response detected in the vaccinated chickens may be directed against this antigen and that the antitumor antigen immunity may play a role in the mechanism of vaccine protection against lymphoma development by pathogenic MDV.
mesh_terms: D000818:Animals; D000951:Antigens, Neoplasm / Q000008:administration & dosage*; D000954:Antigens, Surface; D000956:Antigens, Viral / Q000008:administration & dosage*; D002645:Chickens; D003602:Cytotoxicity, Immunologic; D008381:Herpesvirus 2, Gallid / Q000276:immunology*; D006358:Hot Temperature; D007111:Immunity, Cellular; D066298:In Vitro Techniques; D008380:Marek Disease / Q000276:immunology*; D009439:Neuraminidase / Q000494:pharmacology; D013601:T-Lymphocytes / Q000276:immunology; D014765:Viral Vaccines / Q000494:pharmacology*
chemical_list: D000951:Antigens, Neoplasm; D000954:Antigens, Surface; D000956:Antigens, Viral; D014765:Viral Vaccines; D009439:Neuraminidase